Athersys, Inc. (NASDAQ:ATHX) traded up 3.7% on Thursday . The company traded as high as $1.65 and last traded at $1.55. 433,103 shares traded hands during trading, a decline of 28% from the average session volume of 601,808 shares. The stock had previously closed at $1.61.
A number of equities research analysts have weighed in on the company. ValuEngine downgraded Athersys from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Maxim Group set a $12.00 price objective on Athersys and gave the company a “buy” rating in a report on Thursday, November 16th.
In other news, COO William Lehmann, Jr. sold 14,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $1.80, for a total value of $25,200.00. Following the transaction, the chief operating officer now directly owns 503,712 shares of the company’s stock, valued at approximately $906,681.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 29,000 shares of company stock worth $51,075 over the last three months. 9.40% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Athersys (ATHX) Trading -3.7% Higher” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2018/03/10/athersys-athx-trading-3-7-higher.html.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.